Artificial Intelligence in Drug Discovery Market Size & Share 2026-2035

Artificial Intelligence in Drug Discovery Market Size

The artificial intelligence in drug discovery market was valued at USD 3.1 billion in 2025, is expected to reach USD 4 billion in 2026, and is projected to expand to USD 43.9 billion by 2035 at a CAGR of 30.5% during 2026-2035.

The scale-up reflects a change in where computational methods are deployed: AI is moving beyond isolated virtual-screening exercises toward integrated target discovery, molecular design, property prediction, and preclinical decision support.

Economics remain a central adoption catalyst. Pharmaceutical R&D must absorb a long development cycle and substantial attrition before a product reaches approval. ^{[1]Congressional Budget Office, Research and Development in the Pharmaceutical Industry, 2021, cbo.gov} A 2024 assessment placed the cost of bringing a novel drug to market above USD 3.5 billion when failures and capital costs are included. AI platforms do not eliminate clinical risk, but they can narrow experimental work to candidates with stronger predicted binding, developability, or safety characteristics. The commercial value therefore lies less in replacing laboratory science than in concentrating laboratory capacity on a smaller and better-prioritized set of hypotheses.

Technical progress has strengthened the case for using AI at earlier discovery stages. AlphaFold 3 broadened structure prediction to interactions involving proteins, small molecules, nucleic acids, and antibodies, providing a more useful basis for structure-informed design than protein-only modeling. ^{[2]National Institutes of Health PubMed Central, AlphaFold 3: Transformative Advances in Drug Discovery, 2024, pmc.ncbi.nlm.nih.gov} Clinical evidence is also beginning to test the underlying proposition. Insilico Medicine reported Phase IIa findings for rentosertib in idiopathic pulmonary fibrosis in 2025, linking a generative-AI discovery program to a peer-reviewed clinical proof point. ^{[3]EurekAlert! / Insilico Medicine, Insilico Medicine announces Nature Medicine publication of Phase IIa results evaluating rentosertib for idiopathic pulmonary fibrosis, June 3, 2025, sciencesources.eurekalert.org} Alongside these developments, equity funding for AI in drug R&D reached USD 3.8 billion in 2024, indicating continued capital support for platform development and pipeline advancement. ^{[4]CB Insights, The AI in Drug R&D Market Map, 2024, cbinsights.com}

The regulatory setting is becoming more defined, although it remains demanding. FDA's January 2025 draft guidance addresses the credibility of AI models used to support regulatory decision-making for drugs and biological products; FDA noted experience with more than 500 submissions containing AI components between 2016 and 2023. ^{[5]U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Artificial Intelligence for Drug Development, January 7, 2025, fda.gov} This does not create a separate approval route for discovery software. Instead, it increases the importance of traceability, data provenance, and model-performance documentation when AI-derived evidence contributes to downstream development and regulatory packages.

Software accounted for 67.9% of market revenue in 2025, while machine learning represented 82.6% of technology demand. The top five participants together held approximately 11.8% of the market, leaving room for infrastructure providers, computational-chemistry specialists, AI-native discovery companies, and disease-focused developers to coexist without a single controlling platform.

Funding and regulatory activity reinforce, rather than independently create, this transition. The USD 3.8 billion invested in AI drug R&D during 2024 supplies the capital needed to build data assets and advance programs, whereas FDA's draft guidance signals that credibility evidence will increasingly be part of the operating model. Growth is consequently likely to favor vendors that can couple model performance with reproducible experimental validation, auditable datasets, and development-ready documentation, rather than vendors offering molecular generation in isolation.

Key Drivers

Complex chronic-disease biology is raising the value of computational prioritization.

Global cancer incidence reached 20.6 million new cases in 2024, and IARC projects 34.4 million cases by 2050. Oncology generates unusually large and heterogeneous genomic, molecular, and clinical datasets, but it also presents a broad target space in which conventional experimental screening can be slow and expensive. AI can prioritize targets, stratify biological hypotheses, and screen candidate libraries before wet-lab campaigns begin. This supports the concentration of AI discovery spending in oncology, which represented USD 1.4 billion in 2025.

Digitized biological data expands the usable discovery substrate.

Structure databases, sequencing outputs, phenotypic imaging, assay results, and curated scientific literature give models more inputs than conventional medicinal-chemistry workflows can review manually. AlphaFold 3 is particularly relevant because its modeling scope extends beyond isolated proteins to molecular interactions that influence binding and mechanism. The advantage is not the volume of data alone. It is the ability to connect otherwise separate evidence streams into a target or compound hypothesis that can be tested experimentally.

Algorithm and compute improvements are lowering the cost of advanced modeling.

NVIDIA released BioNeMo as an open framework for digital-biology workloads in November 2024, enabling organizations to train and deploy biological foundation models on accelerated infrastructure. ^{[6]NVIDIA, NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry, November 18, 2024, investor.nvidia.com} Faster inference and more accessible model-development tools broaden the addressable customer base beyond organizations that maintain dedicated internal high-performance computing environments. This shifts the competitive question from access to compute toward the quality of proprietary data, scientific workflows, and validation capability.

Technology-pharma alliances are converting platform capability into contracted demand.

Isomorphic Labs announced a multi-target discovery collaboration with Novartis in January 2024, and BenevolentAI reported additional target progression under its AstraZeneca collaboration in June 2024. These arrangements demonstrate how pharmaceutical companies can obtain AI capability without building every model, data pipeline, and scientific team internally. They also make milestones, research payments, and follow-on programs important revenue mechanisms for platform providers, particularly where partners require biological validation rather than standalone software access.

Key Restraints

Data quality and integration constrain the transferability of AI outputs.

Drug discovery data are generated across laboratories, assay formats, cell systems, and protocols that may not be directly comparable. Models trained on fragmented data can appear accurate in a narrow internal setting yet perform poorly when transferred to a new target, modality, or customer dataset. For pharmaceutical organizations, the constraint often begins before model selection: historical assay results, failed compounds, and clinical biomarker data must be standardized, governed, and made accessible across internal silos. That requirement favors vendors able to support data engineering and scientific curation alongside modeling.

Regulatory and ethical concerns raise the burden of evidence around AI-derived decisions.

FDA's draft guidance emphasizes context-specific assessment of AI model credibility for regulatory decision-making. Although discovery tools are not regulated as products simply because they use AI, sponsors must still explain and defend the evidence underlying candidate selection, nonclinical conclusions, and development decisions. Black-box behavior, bias in training datasets, data-rights limitations, and uncertainty over intellectual-property ownership can slow adoption where an AI recommendation cannot be connected to a scientifically interpretable rationale. The resulting cost is often organizational: scientific, clinical, legal, and regulatory teams must agree on when model output is sufficiently reliable to influence an expensive program.

This creates an asymmetric commercial outcome. Organizations that treat biological data as a governed product, with provenance and experimental context preserved, can improve both model performance and the defensibility of downstream decisions. Vendors that cannot demonstrate this chain may still win exploratory projects, but they face a more difficult path to repeatable, development-stage contracts. The restraint therefore shifts value toward integrated platforms, data-management capability, and workflows that preserve the link between an algorithmic prediction and a reproducible laboratory result.

Artificial Intelligence in Drug Discovery Market Segment Analysis

By Component

Software held 67.9% of market revenue in 2025 and is projected to expand at a 30.2% CAGR. Its lead reflects the broad use of licensed platforms for target identification, virtual screening, molecular generation, and property prediction. Cloud-based software represented 74.3% of software demand, allowing customers to scale intensive workloads without committing to permanent internal compute infrastructure. On-premise deployment remains relevant where proprietary compound libraries, sensitive patient data, or enterprise governance requirements limit external hosting.

Services are projected to grow at a 31.1% CAGR. This faster rate indicates that customers increasingly require scientific interpretation, model customization, data curation, and experimental follow-through in addition to software licenses. The shift is commercially important because services can align supplier compensation with defined program outcomes, such as a validated target, optimized lead series, or preclinical candidate package.

By Technology

Machine learning accounted for 82.6% of technology revenue in 2025, and deep learning made up 66.3% of the machine-learning segment. Deep-learning architectures are well suited to the graph, sequence, image, and multimodal data structures common in molecular and biological science. Their adoption is supported by structure-prediction advances such as AlphaFold 3 and the growing availability of accelerated foundation-model frameworks.

Other approaches retain distinct roles rather than becoming obsolete. Physics-based simulation can provide mechanistic checks on AI-generated hypotheses, while knowledge graphs can preserve interpretable biological relationships. The opportunity is therefore increasingly hybrid: organizations can use machine learning to explore broad chemical or biological spaces, then apply more interpretable or physically grounded methods to prioritize the outputs most suitable for experimental testing.

By Application

Molecular library screening generated USD 1.2 billion in 2025 and remains the largest application because it can be incorporated into established hit-finding workflows. Virtual screening reduces the number of compounds that need to be purchased, synthesized, or tested experimentally, offering a visible productivity case for organizations with substantial compound collections.

Target identification is strategically significant because weak target biology is difficult to correct later in development. BenevolentAI's AstraZeneca collaboration, which produced further target progression in systemic lupus erythematosus in 2024, illustrates the commercial relevance of AI-supported biological hypothesis generation. De novo drug design is smaller but projected to expand at a 30.4% CAGR, the highest among applications. The segment's growth depends on whether generated structures can repeatedly meet potency, selectivity, synthesis, and developability requirements, rather than merely appear novel in silico. Insilico's rentosertib program is therefore meaningful as a clinical proof point for the category.

Oncology led with USD 1.4 billion in 2025. Its position is reinforced by the volume of molecular data, the biological diversity across tumor types, and sustained demand for differentiated targets and biomarker-defined therapies. The increasing global cancer burden adds urgency to this search, but the segment's AI intensity is primarily explained by the need to integrate highly heterogeneous genomic and phenotypic information.

Neurodegenerative, inflammatory, infectious, metabolic, rare, and cardiovascular diseases create different data and validation conditions. Rare diseases can benefit from AI-enabled interpretation of limited genetic evidence, but sparse clinical and experimental datasets may reduce model reliability. Inflammatory diseases offer opportunities where pathway biology and biomarker evidence are comparatively well characterized. The use case is consequently therapeutic-area specific: AI creates most value where it can improve a clearly identified decision bottleneck rather than where it is applied indiscriminately.

By End Use

Pharmaceutical and biotechnology companies held 52.8% of market revenue in 2025. These customers use AI both to improve internal discovery productivity and to access specialized platforms through alliances. Their purchasing decisions are shaped by integration with existing data, compound libraries, therapeutic priorities, and development governance.

CROs are projected to record a 31.0% CAGR, the fastest among end users. By embedding AI in screening, lead optimization, and preclinical support services, CROs can offer smaller biotechs access to advanced discovery workflows without requiring them to procure and operate a full platform. This model can expand adoption among organizations for which a direct enterprise software deployment would be too costly or technically demanding.

Machine learning's 82.6% share confirms that data-trained models remain the market's core technology base, but model access is becoming less exclusive as cloud software and accelerated frameworks spread. Competitive advantage will therefore depend increasingly on an operator's ability to connect models to proprietary biological data, synthesis-aware design, and fast experimental feedback. CROs that can make that loop operational may gain more than a productivity tool; they may become an access channel for de novo design among customers with limited internal computational infrastructure.

Artificial Intelligence in Drug Discovery Market Regional Analysis

North America

North America accounted for 47.7% of market revenue in 2025. The U.S. generated USD 0.7 billion in 2022, USD 0.8 billion in 2023, USD 1.1 billion in 2024, and USD 1.4 billion in 2025. Its lead is supported by the concentration of pharmaceutical R&D, venture funding, advanced computing infrastructure, and AI drug-discovery companies. FDA's active work on AI-related regulatory considerations also gives U.S. sponsors a direct channel for engaging with the evidence standards likely to affect AI-supported development.

Canada contributes a distinct research and platform-development base, supported by AI and life-sciences clusters. The 2025 collaboration between Variational AI and Merck illustrates the role of Canadian generative-AI developers in cross-border pharmaceutical discovery programs. Across North America, the commercial advantage lies in the ability to finance high-cost platform development and advance AI-originated programs toward clinical evaluation.

Europe

Europe generated USD 1.0 billion in 2025. The region combines established pharmaceutical buyers with a large academic and computational-biology base. The UK has particular relevance through companies such as Isomorphic Labs and BenevolentAI, whose Novartis and AstraZeneca-related activity demonstrates the region's ability to create globally relevant discovery partnerships. Germany, France, Spain, Italy, the Netherlands, and the rest of Europe contribute through pharmaceutical manufacturing, life-sciences research, digital-health infrastructure, and cross-border research networks.

European market development is shaped by a dual requirement: discovery platforms must show scientific utility while also meeting increasingly formal expectations around AI governance and data stewardship. This can slow implementation where cross-border health data are required, but it can also reward vendors able to provide transparent documentation and strong data controls. Sanofi's participation in Enveda's Series C financing in February 2025 illustrates continued European pharmaceutical interest in AI-enabled discovery platforms.

Asia Pacific

Asia Pacific is the fastest-growing region, with a projected 31.2% CAGR. China, Japan, India, Australia, South Korea, and the rest of Asia Pacific each contribute different assets to the regional ecosystem. China combines growing biopharma capacity with clinical-development scale, while Japan offers established pharmaceutical companies and a mature external-partnership market. Insilico's clinical work across China and Australia shows that AI-originated programs can use the region both for development execution and for geographically diversified clinical evidence generation.

India's opportunity is closely linked to its CRO and technical-services base. AI tools can enable service providers to add computational screening, design, and prediction capabilities to established research delivery models. Australia and South Korea strengthen the region through clinical research infrastructure, research institutions, and technology adoption. The regional growth premium reflects a lower starting point combined with increasing access to cloud computing and global AI platforms, rather than a uniform shift in all countries' discovery capabilities.

Latin America

Latin America remains a smaller market led by Brazil, Mexico, Argentina, and the rest of the region. Adoption is most likely to progress through research institutions, multinational pharmaceutical relationships, and CRO service models rather than through large numbers of fully integrated AI-native drug developers. Brazil's scientific institutions and pharmaceutical base provide a foundation for computational biology and preclinical collaboration, while Mexico benefits from proximity to North American research networks and growing outsourced-research activity. Argentina contributes specialized academic and computational capabilities.

The region's commercial constraint is the limited availability of large, standardized proprietary datasets and advanced discovery infrastructure relative to North America and Europe. Providers that offer cloud-based, modular capabilities and can work through CRO partners are better positioned than suppliers that require extensive internal data engineering before value can be demonstrated.

Middle East & Africa

Middle East & Africa is an early-stage market encompassing South Africa, Saudi Arabia, the UAE, and the rest of the region. South Africa has the strongest established clinical-research base among the named markets, whereas Saudi Arabia and the UAE are building life-sciences, healthcare, and AI capacity through national investment programs. The immediate opportunity is concentrated in research infrastructure, academic partnerships, and access to cloud-enabled modeling rather than broad-scale internal drug-discovery platform ownership.

Market development will depend on whether investment in health data, genomics, and research capacity is converted into interoperable datasets and repeatable development programs. For international platform providers, partnership structures that build local capability and manage data-governance requirements are likely to be more practical than a uniform direct-sales approach.

The regional pattern has an important operational implication. AI can reduce the minimum infrastructure required to participate in early discovery, but it does not remove the need for high-quality data, experimental validation, and regulatory-grade development capability. China and India may gain from scale in biopharma and research services, while Japan, Australia, and South Korea can contribute specialized pharmaceutical and clinical capabilities. Suppliers that differentiate regional offers by data-access conditions, deployment model, and partner ecosystem are more likely to capture the growth premium than those treating Asia Pacific as a single homogeneous market.

Artificial Intelligence in Drug Discovery Market Share & Competitive Landscape

The market remains fragmented, with the five largest participants collectively accounting for approximately 11.8% of 2025 revenue. Competition occurs across several layers: AI infrastructure and cloud delivery; computational chemistry and simulation; target discovery and molecular design; disease-specific platform development; and integrated discovery-to-clinic models. A company's positioning is increasingly determined by the combination of data access, model quality, experimental validation, and pharmaceutical partnerships.

Isomorphic Labs, an Alphabet company, is positioned around structure-informed drug design and the application of AlphaFold-related advances to therapeutic development. Its USD 600 million Series A financing in March 2025 and its collaborations with Novartis and Eli Lilly illustrate the capital intensity and partnership-led economics of advancing an AI design engine into clinical programs. Microsoft and NVIDIA operate primarily at the enabling-infrastructure layer: Microsoft provides cloud and research-computing environments, while NVIDIA supplies accelerated hardware and BioNeMo tools for biological foundation models. Their alliance is relevant because it reduces the integration burden for organizations seeking scalable AI capabilities without constructing every element of the technology stack independently.

IBM brings enterprise AI, hybrid-cloud, and scientific-computing capabilities to customers that require data governance alongside scalable analytics. Schrödinger competes from a different starting point, combining physics-based simulation with AI-supported discovery. Its 2025 results included USD 199.5 million in software revenue and USD 56.4 million in drug-discovery revenue, demonstrating the value of a commercially established simulation platform with collaboration exposure. These companies compete less on a single model architecture than on whether their platforms can be incorporated into validated scientific workflows.

Recursion Pharmaceuticals uses an integrated phenomics, genomics, and AI platform, combining data generation with computational interpretation. Its 2024 annual report describes a pipeline and platform strategy that extends AI use across discovery and development activities. Insilico Medicine has differentiated through its Pharma.AI platform and clinical progression of rentosertib, alongside the 2025 Phase I update for ISM5411 and integration of its Nach01 model with Microsoft Discovery. BenevolentAI's knowledge-graph-oriented approach remains centered on biological target discovery and partnership outputs, including continued progress with AstraZeneca.

Atomwise focuses on structure-based binding prediction and virtual screening. Insitro combines machine learning with high-throughput human cellular models for target discovery and validation. Deep Genomics concentrates on AI-guided RNA therapeutics and genetic disease biology, while Iktos focuses on generative molecular design and synthetic accessibility. Deargen develops AI-supported target and compound interaction capabilities, with a presence in Asia-Pacific drug-discovery activity. These companies illustrate how specialized modality, data type, or workflow depth can create differentiation even when foundation-model technologies become more widely accessible.

9Bio Therapeutics, Aureka Biotechnologies, CellCodex Technology Limited, chAIron, DenovAI Biotech, Examol, Helical.AI, Orakl Oncology, and Therenia represent the emerging company tier within the authorized competitive scope. Their strategic relevance lies in focused approaches to structural biology, phenotypic analysis, oncology, molecular design, and other narrower discovery problems. In a fragmented market, focused platforms may secure partnerships by solving a specific scientific bottleneck more effectively than broad horizontal systems. Their ability to scale will depend on proprietary data, validated outputs, and evidence that their tools improve decisions in real discovery programs.

Recent Industry Developments

• March 31, 2025 - Isomorphic Labs announced a USD 600 million Series A financing to expand its AI drug-design engine and advance therapeutic programs toward the clinic.
• June 3, 2025 - Insilico Medicine announced publication of Phase IIa rentosertib results in *Nature Medicine*, reporting a clinical proof point for an AI-discovered and AI-designed program in idiopathic pulmonary fibrosis.
• January 14, 2025 - Insilico Medicine announced integration of its Nach01 multimodal foundation model with Microsoft Discovery.